Latest Acromegaly Stories
DALLAS, April 7, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "OpportunityAnalyzer: Acromegaly and Gigantism - Opportunity Analysis and Forecast to 2018" therapeutic
LONDON, April 2, 2015 /PRNewswire/ -- SummaryAcromegaly and gigantism are rare disorders of the pituitary gland characterized by the hypersecretion of growth hormone (GH).
Proven Business Leader to Oversee Commercialization of Octreotide Capsules NEWTON, Mass. and JERUSALEM, March 16, 2015 /PRNewswire/ -- Chiasma, Inc., a U.S.
Two studies presented at ENDO 2015 contribute to growing body of knowledge about acromegaly treatment NEWTON, Mass. and JERUSALEM, March 5, 2015 /PRNewswire/ -- Chiasma, Inc., a U.S.
NEWTON, Mass. and JERUSALEM, Feb. 27, 2015 /PRNewswire/ -- Chiasma, Inc., a U.S.
NEWTON, Mass. and JERUSALEM, Feb. 24, 2015 /PRNewswire-USNewswire/ -- Chiasma, Inc., a U.S.
-- Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels(1) -- Signifor LAR, a next-generation somatostatin
ReportsnReports.com adds EpiCast Report Acromegaly and Gigantism Epidemiology Forecast to 2023 to its store.
- Primary efficacy endpoint met with a statistically significant reduction of sIGF-I levels of 26% at the 400mg/week dose (P
- A person or thing gazed at with wonder or curiosity, especially of a scornful kind.